ClinicalTrials.gg
CompletedNCT01258907Updated Nov 2, 2016

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

A Phase 2 interventional study of MLDL1278A and MLDL1278A in Atherosclerosis, sponsored by Genentech, Inc.. Completed at 24 sites in 2 countries. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.

Enrollment
149th of 328
147 · median 119
Started
2010
with 20 others
Phase 2
63 of 468
7 open now
Registered
210th of 468
by date

Among the 468 studies in Atherosclerosis with a site in United States, this one is the 149th largest by enrollment of the 328 interventional ones that give a count, is one of 21 that started in 2010, is one of 63 in phase 2, and was the 210th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 468 studies in Atherosclerosis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase II (proof-of-activity), double-blind, placebo-controlled, randomized, multicenter study of MLDL1278A (also known as BI-204) involving patients on standard-of-care therapy for atherosclerotic cardiovascular disease with evidence of vascular inflammation, as quantified by FDG-PET/CT.

03

Conditions studied

  • Atherosclerosis

Browse trials for

Keywords

  • BI-204
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of qualifying vessel (carotid or aortic) plaque inflammation
  • Documented atherosclerotic vascular disease clinically stable for at least 3 months prior to screening or type 2 diabetes mellitus with elevated cardiovascular risk
  • Use of a stable dose of statin therapy for at least 6 weeks prior to screening. Patients must be capable of maintaining statin therapy at a current dose level from screening until the last follow-up visit.
  • For patients taking angiotensin-converting enzyme (ACE) inhibitors (ACE-I) or angiotensin-receptor blockers (ARBs), non-statin lipid-modifying therapy, thiazolidinediones, inhaled , or leukotriene modifying agents, use of a stable dose for at least 6 weeks prior to screening and capable of continuing with that dose for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Occurrence of a cardiovascular event \< 6 months prior to screening
  • Pregnant, planning to become pregnant during the study, or breastfeeding
  • abnormal laboratory values or abnormal or vital signs
  • History of anaphylactic reactions
  • Newly discovered Type 2 diabetes mellitus (T2DM) (prior to study entry) or medical treatment for T2DM started \< 3 months prior to study entry
  • Use of insulin, (oral, rectal, or injectable), or other medications
  • Current or recent (within 4 weeks prior to screening) infection, including signs, symptoms or serology of any infection, including , or C
  • Impaired renal function
  • History of within 2 years prior to screening
  • Current life-threatening condition other than vascular disease that may prevent a patient from completing the study
  • Use of an drug or biologic within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study medication
  • Exposure to substantial radiation within 12 months prior to screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    A

    Drug: MLDL1278A · Drug: statin, stable dose

  • Experimental
    B

    Drug: MLDL1278A · Drug: statin, stable dose

  • Placebo comparator
    C

    Drug: placebo · Drug: statin, stable dose

Interventions

  • Single intravenous dose

  • Repeating intravenous dose

  • Drugplacebo

    Repeating intravenous dose

  • Drugstatin, stable dose

    Repeating oral dose

06

What researchers measure

Primary outcomes

  1. Change in TBR as measured by FDG-PET/CT

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Incidence and severity of adverse events and clinical laboratory abnormalities as a measure of safety and tolerability of MLDL1278A

    Time frame: Throughout study or until early discontinuation

  2. Effects of MLDL1278A on inflammatory and metabolic biomarkers

    Time frame: Throughout study or until early discontinuation

07

Study locations

24 sites
  • Torrance, California 90502, United States
  • Colorado Springs, Colorado 80904, United States
  • Washington, District of Columbia 20010, United States
  • Gainesville, Florida 32605, United States
  • Jacksonville, Florida 32216, United States
  • Indianapolis, Indiana 46260, United States
  • Boston, Massachusetts 02114, United States
  • Haverhill, Massachusetts 01830, United States
  • Royal Oak, Michigan 48073, United States
  • Minneapolis, Minnesota 55455, United States
  • Saint Paul, Minnesota 55102, United States
  • Kansas City, Missouri 64111, United States
  • Newington, New Hampshire 03801, United States
  • New York, New York 10001, United States
  • New York, New York 10029, United States
  • North Massapequa, New York 11758, United States
  • Cincinnati, Ohio 45219, United States
  • Cincinnati, Ohio 45227, United States
  • Portland, Oregon 97225-3411, United States
  • Portland, Oregon 97239, United States
  • Houston, Texas 77002, United States
  • Houston, Texas 77030, United States
  • Ottawa, Ontario K1Y 4W7, Canada
  • Montreal, Quebec H1T 1C8, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010 and a primary completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2010
First posted
Dec 13, 2010
Start
Mar 2010
Primary completionActual
Jul 2012
Results delay requested
Aug 20, 2013
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01258907
Lead sponsor
Genentech, Inc.
Collaborators
BioInvent International AB
Responsible party
Sponsor
First posted
Dec 13, 2010
Start date
Mar 2010
Primary completion
Jul 2012
Last update
Nov 2, 2016

Study contacts

Joshua Lehrer-Graiwer, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLDL1278A

Start the discussion